Based on the Aurobindo Pharma Limited stock forecast from 4 analysts, the average analyst target price for Aurobindo Pharma Limited is INR 1,117.00 over the next 12 months. Aurobindo Pharma Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aurobindo Pharma Limited is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, Aurobindo Pharma Limited’s stock price was INR 1,103.40. Aurobindo Pharma Limited’s stock price has changed by -1.00% over the past week, +8.19% over the past month and +79.87% over the last year.
No recent analyst target price found for Aurobindo Pharma Limited
No recent average analyst rating found for Aurobindo Pharma Limited
Company Overview Aurobindo Pharma Limited
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries. In addition, it offers AuroSource, a contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for penicillin's, cephalosporins, and non beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India. Address: Galaxy, Plot No. 1, Hyderabad, India, 500032 Read Less
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmace...Read More
Frequently Asked Questions About Aurobindo Pharma Limited (AUROPHARMA:NSE) Stock
Based on ratings from 4 analysts Aurobindo Pharma Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 5 buy, sell and 1 hold ratings.
AUROPHARMA:NSE stock's dividend yield is 0.42%.
Our analysis grades AUROPHARMA:NSE stock's dividend yield at F. This means that AUROPHARMA:NSE stock's dividend yield is above 40% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AUROPHARMA:NSE may be a average dividend stock for its sector.
Based on targets from 4 analysts, the average taret price for AUROPHARMA:NSE is INR 1,117.00 over the next 12 months. The maximum analyst target price is INR 1185 while the minimum anlayst target price is INR 1037.
AUROPHARMA:NSE stock's Price/Earning ratio is 23.35.
Our analysis grades AUROPHARMA:NSE stock's Price / Earning ratio at C+. This means that AUROPHARMA:NSE stock's Price/Earning ratio is above 23% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AUROPHARMA:NSE may be undervalued for its sector.
The last closing price of AUROPHARMA:NSE's stock was INR 1,103.40.
The most recent market capitalization for AUROPHARMA:NSE is INR 646.53B.
Based on targets from 4 analysts, the average taret price for AUROPHARMA:NSE is projected at INR 1,117.00 over the next 12 months.
This means that AUROPHARMA:NSE's stock price may go up by +1.23% over the next 12 months.
We can't find any ETFs which contains Aurobindo Pharma Limited's stock.
As per our most recent records Aurobindo Pharma Limited has 23,451 Employees.
Aurobindo Pharma Limited's registered address is Galaxy, Plot No. 1, Hyderabad, India, 500032.
You can get more information about it from Aurobindo Pharma Limited's website at https://www.aurobindo.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Poor return on equity
The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AUROPHARMA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
